Updated:
EA Pharma
EA Pharma was established in 2016 and is headquartered in Tokyo, Japan. It was formed through the integration of gastrointestinal business units.
EA Pharma
EA Pharma was established in 2016 and is headquartered in Tokyo, Japan. It was formed through the integration of gastrointestinal business units. It operates as a result of the Eisai Group and the Ajinomoto Group integration. EA Pharma maintains a strategic licensing partnership with Newron Pharmaceuticals. Motion Equity Partners holds private equity ownership of the related EA Pharma France entity. The firm supports ISPNO Family Day and Japan Children's Cancer Group initiatives. The firm lists one additional industrial office in Fukushima, Japan. No recent operational events from the last 24 months are recorded in available sources.
General information
Firm type
Corporate Investor
Year founded
2016
AUM
Undisclosed
Location
Region
Asia
Country
Japan
City
Tokyo
Corporate office
Tokyo, Japan
Additional offices
Fukushima Business Office, Fukushima, Japan
Sector focus
Frequently asked questions
Who are the primary owners of EA Pharma?
Eisai Co., Ltd. holds a 60 percent stake and Ajinomoto Co., Inc. holds the remaining 40 percent.
What is EA Pharma's relationship to Motion Equity Partners?
Motion Equity Partners acts as private equity owner of the EA Pharma France entity within the Olyos Group.
Does EA Pharma maintain any industry association memberships?
EA Pharma is a member of the Clinical Data Interchange Standards Consortium.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: